OncLive® On Air

Highlights from the PER® CME activity "From Molecular Insights to Clinical Impact: Translating the Latest Advances in Menin Inhibitors Into Practice" — this podcast is not certified for credit. To participate in the full accredited activity and earn CME credit, use the link below.

In this podcast, experts Naval G. Daver, MD; Amir Fathi, MD; Guillermo Garcia-Manero, MD; and Aditi Shastri, MD, discuss current applications for menin inhibitors in patients with acute leukemia, combination approaches under investigation, and managing treatment-related adverse events with menin inhibitors.

Earn CME credit by completing the full accredited activity (available through April 27, 2027):
https://www.gotoper.com/molecularinsights26menin-activity

This podcast, including the narration, was developed by PER® (Physicians’ Education Resource®, LLC) editorial staff from the full online CME activity developed with these faculty. The narration was voiced by a PER staff member or by an AI tool. The podcast contains no product advertising. The full activity is supported by educational grants from Kura Oncology and Syndax Pharmaceuticals, Inc.

This content is for educational purposes only and is not a substitute for the independent clinical judgment of a health care professional. Faculty may discuss investigational or off-label uses; consult prescribing information for any products discussed.

Dr Stover began by explaining that the RAS/MAP kinase pathway is a well-established oncogenic signaling cascade that regulates cancer cell proliferation, survival, and invasion. Advances in drug development are now making it possible to target multiple points along this pathway, including RAS itself, once considered “undruggable.”

Drs Matulonis and Stover emphasized that RAS/MAP kinase pathway alterations are relatively common across gynecologic malignancies, occurring in at least 20% of cases overall. Certain disease subtypes have particularly high prevalence, including low-grade serous ovarian cancer, mucinous ovarian cancer, and subsets of endometrial and cervical cancers. Clinically, activation of this pathway is generally associated with more aggressive disease and reduced sensitivity to conventional chemotherapy, although nuances exist. 

The conversation also explored emerging therapeutic strategies targeting this pathway. Early developmental success with MEK inhibitors—such as trametinib (Mekinist), selumetinib (Koselugo), and binimetinib (Mektovi)—has translated to meaningful clinical benefit, particularly in low-grade serous ovarian cancer. More recently, combination approaches have shown promise, including the dual RAF/MEK inhibitor avutometinib paired with the FAK inhibitor defactinib (Avmapki Fakzynja Co-pack). This combination addresses adaptive resistance mechanisms and has generated improved response rates and disease control, leading to its May 2025 FDA approval in this setting.

Looking ahead, Dr Stover highlighted the development of direct RAS inhibitors as one of the most exciting advances in oncology. Dr Stover concluded by outlining key areas of ongoing research, including understanding differential sensitivity across tumor subtypes, identifying mechanisms of resistance, and optimizing combination strategies. 

Highlights from the PER® CME activity "Medical Crossfire®: Advancing Personalized Care in TNBC—Integrating Biomarkers, Clinical Evidence, and Emerging Therapies" — this podcast is not certified for credit. To participate in the full accredited activity and earn CME credit, use the link below.

In this podcast, experts Adam Brufsky, MD, PhD; Kamel Abou Hussein, MD; and Priyanka Sharma, MD, FASCO, discuss personalizing care in early-stage triple-negative breast cancer (TNBC) and the evolving first-line strategies and their implications for downstream sequencing in metastatic TNBC.

Earn CME credit by completing the full accredited activity (available through April 24, 2027):
https://www.gotoper.com/mbcc26tnbc-activity

This podcast, including the narration, was developed by PER® (Physicians’ Education Resource®, LLC) editorial staff from the full online CME activity developed with these faculty. The narration was voiced by a PER staff member or by an AI tool. The podcast contains no product advertising. The full activity is supported by an educational grant from Gilead Sciences, Inc.

This content is for educational purposes only and is not a substitute for the independent clinical judgment of a health care professional. Faculty may discuss investigational or off-label uses; consult prescribing information for any products discussed.

Highlights from the PER® CME activity "Medical Crossfire® Expanding Options, Evolving Challenges in Advanced HR+/HER2– Breast Cancer: How Experts Apply the Latest Data" — this podcast is not certified for credit. To participate in the full accredited activity and earn CME credit, use the link below.

In this podcast, experts Kevin Kalinsky, MD, MS; Adam Brufsky, MD, PhD; Kelly Elizabeth McCann, MD, PhD; and Sara Nunnery, MD, MSCI, review pivotal clinical trials investigating novel endocrine therapies and targeted combination regimens for hormone receptor-positive, HER2-negative metastatic breast cancer, and discuss strategies for selecting the optimal treatment approach for individual patients.

Earn CME credit by completing the full accredited activity (available through April 23, 2027):
https://www.gotoper.com/courses/medical-crossfire-expanding-options-evolving-challenges-in-advanced-hrher2-breast-cancer-how-experts-apply-the-latest-data-vv3z

This podcast, including the narration, was developed by PER® (Physicians’ Education Resource®, LLC) editorial staff from the full online CME activity developed with these faculty. The narration was voiced by a PER staff member or by an AI tool. The podcast contains no product advertising. The full activity is supported by educational grants from AstraZeneca Pharmaceuticals; Daiichi Sankyo, Inc; Genentech, Inc; Lilly; and Stemline Therapeutics.

This content is for educational purposes only and is not a substitute for the independent clinical judgment of a health care professional. Faculty may discuss investigational or off-label uses; consult prescribing information for any products discussed.

Highlights from the PER® CME activity "Show Me the Data: Translating Clinical and Practice-Based Evidence on Oral SERDs Into Everyday Care for HR+/HER2– Metastatic Breast Cancer" — this podcast is not certified for credit. To participate in the full accredited activity and earn CME credit, use the link below.

In this podcast, experts Reshma L. Mahtani, DO; Kamel Abou Hussein, MD; and Irene Kang, MD; discuss how to translate clinical and real-world evidence regarding oral selective estrogen receptor degraders (SERDs) and targeted combination therapies into everyday clinical practice for managing hormone receptor–positive/HER2-negative metastatic breast cancer.

Earn CME credit by completing the full accredited activity (available through April 21, 2027):
https://www.gotoper.com/courses/show-me-the-data-translating-clinical-and-practice-based-evidence-on-oral-serds-into-everyday-care-for-hrher2-metastatic-breast-cancer-zeds">https://www.gotoper.com/courses/show-me-the-data-translating-clinical-and-practice-based-evidence-on-oral-serds-into-everyday-care-for-hrher2-metastatic-breast-cancer-zeds

This podcast, including the narration, was developed by PER® (Physicians’ Education Resource®, LLC) editorial staff from the full online CME activity developed with these faculty. The narration was voiced by a PER staff member or by an AI tool. The podcast contains no product advertising. The full activity is supported by an educational grant from Stemline Therapeutics, Inc.

This content is for educational purposes only and is not a substitute for the independent clinical judgment of a health care professional. Faculty may discuss investigational or off-label uses; consult prescribing information for any products discussed.

Highlights from the PER® CME activity "OncoBytes Adaptive Learning Pathways: Personalizing Treatment Plans to Optimize Adjuvant Therapy in Early-Stage HR+/HER2– Breast Cancer" — this podcast is not certified for credit. To participate in the full accredited activity and earn CME credit, use the link below.

In this podcast, experts Joyce O’Shaughnessy, MD; Virginia Kaklamani, MD, DSc; and Seth A. Wander, MD, PhD; discuss real-world insights into tailoring adjuvant therapy regimens in hormone receptor–positive/HER2-negative (HR+/HER2–) early breast cancer (eBC).

Earn CME credit by completing the full accredited activity (available through April 20, 2027):
https://www.gotoper.com/courses/oncobytes-adaptive-learning-pathways-personalizing-treatment-plans-to-optimize-adjuvant-therapy-in-early-stage-hrher2-breast-cancer

This podcast, including the narration, was developed by PER® (Physicians’ Education Resource®, LLC) editorial staff from the full online CME activity developed with these faculty. The narration was voiced by a PER staff member or by an AI tool. The podcast contains no product advertising. The full activity is supported by educational grants from AstraZeneca Pharmaceuticals and Merck Sharp & Dohme LLC.

This content is for educational purposes only and is not a substitute for the independent clinical judgment of a health care professional. Faculty may discuss investigational or off-label uses; consult prescribing information for any products discussed.

Highlights from the PER® CME activity "Live Tumor Board: Squamous Cell Carcinoma of the Head & Neck - Post-CRT Decisions in the Locally Advanced Setting" — this podcast is not certified for credit. To participate in the full accredited activity and earn CME credit, use the link below.

In this podcast, experts Barbara Burtness, MD; and Quynh-Thu Le, MD, FACR, FASTRO; discuss recent and ongoing trials and key updates in the management of locally advanced head and neck cancer.

Earn CME credit by completing the full accredited activity (available through April 17, 2027):
https://www.gotoper.com/ltb26squamous-activity

This podcast, including the narration, was developed by PER® (Physicians’ Education Resource®, LLC) editorial staff from the full online CME activity developed with these faculty. The narration was voiced by a PER staff member or by an AI tool. The podcast contains no product advertising. The full activity is supported by an educational grant from AstraZeneca Pharmaceuticals.

This content is for educational purposes only and is not a substitute for the independent clinical judgment of a health care professional. Faculty may discuss investigational or off-label uses; consult prescribing information for any products discussed.

Highlights from the PER® CME activity "Medical Crossfire®: PD-L1 Inhibition in Advanced Cutaneous Squamous Cell Carcinoma — Mechanistic Rationale and Clinical Application" — this podcast is not certified for credit. To participate in the full accredited activity and earn CME credit, use the link below.

In this podcast, experts April K.S. Salama, MD; Omid Hamid, MD; James M.G. Larkin, MD, PhD; and Sapna Patel, MD; discuss the data for immune checkpoint inhibitors used to treat advanced cutaneous squamous cell carcinoma, including a review of PD-1 versus PD-L1 inhibition.

Earn CME credit by completing the full accredited activity (available through April 15, 2027):
https://www.gotoper.com/ime26mxfcscc-activity

This podcast, including the narration, was developed by PER® (Physicians’ Education Resource®, LLC) editorial staff from the full online CME activity developed with these faculty. The narration was voiced by a PER staff member or by an AI tool. The podcast contains no product advertising. The full activity is supported by an educational grant from Sun Pharmaceutical Industries, Inc.

This content is for educational purposes only and is not a substitute for the independent clinical judgment of a health care professional. Faculty may discuss investigational or off-label uses; consult prescribing information for any products discussed.